If my second exhibit batch of tablet having potent drug substance has failed in Blend Uniformity and afterwards I need to change the sequence of ingredient addition, and have taken another 3 exhibit batches by revising the BMR and taking OOS at manufacturing plant. do I need to still show this earlier decided manufacturing process in my product development report? or I can directly show the finalised second process? This submission is targeted for Australia and New Zealand.